サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1543967

抗毒素の世界市場

Antivenoms

出版日
ページ情報
英文 196 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.33円
抗毒素の世界市場
出版日: 2024年08月29日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗毒素の世界市場は2030年までに23億米ドルに達する見込み

2023年に14億米ドルと推定される抗毒素の世界市場は、2023年から2030年にかけてCAGR 7.3%で成長し、2030年には23億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるヘビ種は、CAGR 7.4%を記録し、分析期間終了時には20億米ドルに達すると予測されます。サソリ種セグメントの成長率は、分析期間でCAGR 6.9％と推定されます。

米国市場は推定3億6,100万米ドル、中国はCAGR 10.8％で成長予測

米国の抗毒素市場は、2023年に3億6,100万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR 10.8%を牽引し、2030年までに5億4,500万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.9%と6.6%と予測されています。欧州では、ドイツがCAGR 4.6%で成長すると予測されています。

世界の抗毒素市場- 主要動向と促進要因のまとめ

抗毒素の仕組みと重要性

抗毒素は特殊な生物学的製剤であり、ヘビ、クモ、サソリなどの毒性動物に咬まれたり刺されたりすることで起こる中毒の治療に重要な役割を果たします。これらの救命治療は、毒液に含まれる毒素を中和することにより機能します。毒素を放置すると、重篤な病気を引き起こし、死に至ることさえあります。抗毒素を作る過程では、少量の、致死量ではない毒を動物（通常はウマやヒツジ）に注射します。これらの抗体は回収、精製され、抗毒素の製造に使用されます。これらの製品は重要であるにもかかわらず、その製造は複雑で専門的な設備を必要とするため、特に毒に咬まれることが多い地域では、入手が制限されています。抗毒素の背後にある科学は複雑であり、異なる毒には特定の抗体が必要とされるため、万能の抗毒素を製造することは事実上不可能です。この複雑さが、あらゆる種類の毒に有効な治療法を提供するためには、この分野の研究開発が不可欠であることを強調しています。

なぜ抗毒素へのアクセシビリティは依然として世界的課題なのか？

特に毒による咬傷や刺傷が多い新興諸国では、抗毒素へのアクセスが依然として世界の健康上の大きな課題となっています。抗毒素を最も必要としている多くの地域は、不十分なヘルスケアインフラに苦しんでおり、致命的な治療の遅れにつながっています。抗毒素のコストも障壁のひとつです。高価な製造工程を経なければならないため、低所得者層には手の届かない高価格となることが多いです。さらに、この分野への投資不足が抗毒素の供給不足を招き、多くの製薬会社が利益率の低さを理由に生産を中止しています。この欠乏は、抗毒素の保存期間が限られているため、遠隔地での流通や保管が複雑であるという事実によってさらに悪化しています。さらに、毒の多様性と抗毒素製造に必要な特異性により、すべての地域で必要な種類の抗毒素を入手できるわけではないです。こうした課題から、必要不可欠な医薬品へのアクセスを改善し、すべての地域の人々がタイムリーで効果的な治療を受けられるようにするためには、世界の協力が急務であることが浮き彫りになっています。

技術革新は抗毒素開発の限界を克服できるか？

近年、より効果的で広く利用可能な治療法の必要性が認識されるにつれ、抗毒素の研究開発において有望な動向が見られるようになった。バイオテクノロジーの革新は、既存の課題のいくつかを解決しうる新しい抗毒素製造法への道を開きつつあります。例えば、組換えDNA技術の利用により、特定の毒液成分をより正確に標的にできるモノクローナル抗体の作製が可能になり、副作用の少ない、より効果的な抗毒素につながる可能性があります。さらに、合成生物学の進歩により、動物由来に頼らない合成抗毒素の開発が可能になりつつあります。また、毒の分子構造の調査により、より広範な毒を中和できる、より広範なスペクトラムを持つ抗毒素を開発できる可能性も出てきました。このような進歩にもかかわらず、特に低資源環境で広く使用するためにこれらの新技術を確実にスケールアップできるようにするには、大きなハードルが残っています。現在進行中の課題は、こうした科学的ブレークスルーを、世界規模で実施可能な実用的解決策に変換することです。

何が抗毒素市場の成長を牽引しているのか？

抗毒素市場の成長は、技術の進歩と世界のヘルスケアの優先順位のシフトの両方を反映するいくつかの要因によって牽引されています。主な要因の一つは、特にアジア、アフリカ、ラテンアメリカの農村部における蛇咬傷やその他の毒物との遭遇の増加です。このため、効果的な抗毒素に対する需要が高まり、研究開発への投資が促されています。さらに、モノクローナル抗体や合成抗毒素の開発などの技術的進歩により、利用可能な治療の範囲が広がり、より効果的で流通しやすい抗毒素の製造が可能になっています。消費者の行動も変化しており、毒咬傷に対する適時治療の重要性に対する意識の高まりが、これらの製品に対する需要の増加に繋がっています。さらに、政府機関や非政府組織は、毒咬傷を含む顧みられない熱帯病への対応に重点を置いており、これが抗毒素の生産と流通に対する資金提供や支援を後押ししています。最後に、個別化医療の動向は市場に影響を及ぼしており、特定のタイプの毒蛇症に対応できる抗毒素の需要が高まっているため、市場の成長はさらに刺激されています。

調査対象企業の例（注目の46社）

  • Boehringer Ingelheim International GmbH
  • BTG PLC
  • CSL Ltd.
  • Merck & Co., Inc.
  • MicroPharm Ltd.
  • Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP10328

Global Antivenoms Market to Reach US$2.3 Billion by 2030

The global market for Antivenoms estimated at US$1.4 Billion in the year 2023, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2023-2030. Snakes Species, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Scorpions Species segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$361.0 Million While China is Forecast to Grow at 10.8% CAGR

The Antivenoms market in the U.S. is estimated at US$361.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$545.0 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Antivenoms Market - Key Trends and Drivers Summarized

How Do Antivenoms Work and Why Are They So Crucial?

Antivenoms are specialized biological products that play a critical role in treating envenomations caused by bites or stings from venomous animals, including snakes, spiders, and scorpions. These life-saving treatments work by neutralizing the toxins present in the venom, which, if left untreated, can cause severe illness or even death. The process of creating antivenoms involves injecting a small, non-lethal dose of venom into an animal, typically a horse or sheep, which then produces antibodies against the venom. These antibodies are collected, purified, and used to create the antivenom. Despite the importance of these products, their production is complex and requires specialized facilities, which limits their availability, especially in regions where venomous bites are common. The science behind antivenoms is intricate, as different venoms require specific antibodies, making the production of a universal antivenom virtually impossible. This complexity underscores the essential nature of continued research and development in this field to ensure that effective treatments are available for all types of envenomations.

Why Is Accessibility to Antivenoms Still a Global Challenge?

Accessibility to antivenoms remains a significant global health challenge, particularly in developing countries where venomous bites and stings are more common. Many regions that are most in need of antivenoms suffer from inadequate healthcare infrastructure, leading to delays in treatment that can be fatal. The cost of antivenoms is another barrier, as the expensive production process translates into high prices that are often unaffordable for those in low-income areas. Furthermore, the lack of investment in this area has led to a scarcity of antivenom supplies, with many pharmaceutical companies discontinuing production due to low profit margins. This scarcity is exacerbated by the fact that antivenoms have a limited shelf life, which complicates distribution and storage in remote areas. Additionally, the diversity of venoms and the specificity required in antivenom production mean that not all regions have access to the necessary types of antivenom. These challenges highlight the urgent need for global collaboration to improve access to these essential medicines, ensuring that people in all regions can receive timely and effective treatment.

Can Innovation Overcome the Current Limitations in Antivenom Development?

Recent years have seen promising advancements in antivenom research and development, driven by a growing recognition of the need for more effective and widely available treatments. Innovations in biotechnology are paving the way for new methods of antivenom production that could address some of the existing challenges. For instance, the use of recombinant DNA technology allows for the creation of monoclonal antibodies that can target specific venom components more precisely, potentially leading to more effective antivenoms with fewer side effects. Additionally, advances in synthetic biology are enabling the development of synthetic antivenoms that do not rely on animal sources, which could reduce costs and improve accessibility. Research into the molecular structure of venom has also opened up possibilities for creating broader-spectrum antivenoms that can neutralize a wider range of venoms. Despite these advancements, significant hurdles remain, particularly in ensuring that these new technologies can be scaled up for widespread use in low-resource settings. The ongoing challenge is to translate these scientific breakthroughs into practical solutions that can be implemented globally.

What Is Driving the Growth of the Antivenom Market?

The growth in the antivenom market is driven by several factors, reflecting both advancements in technology and shifts in global healthcare priorities. One of the primary drivers is the increasing incidence of snakebites and other venomous encounters, particularly in rural areas of Asia, Africa, and Latin America. This has heightened the demand for effective antivenoms, prompting investment in research and development. Additionally, technological advancements, such as the development of monoclonal antibodies and synthetic antivenoms, are expanding the scope of available treatments, making it possible to produce antivenoms that are more effective and easier to distribute. Consumer behavior is also shifting, with a growing awareness of the importance of timely treatment for venomous bites leading to increased demand for these products. Moreover, governmental and non-governmental organizations are placing greater emphasis on addressing neglected tropical diseases, including venomous bites, which is driving funding and support for antivenom production and distribution. Finally, the trend towards personalized medicine is influencing the market, as there is a growing demand for antivenoms that can be tailored to specific types of envenomations, further stimulating market growth.

Select Competitors (Total 46 Featured) -

  • Boehringer Ingelheim International GmbH
  • BTG PLC
  • CSL Ltd.
  • Merck & Co., Inc.
  • MicroPharm Ltd.
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Antivenoms - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Incidence of Snakebites and Venomous Encounters Spurs Demand for Antivenoms
    • Innovations in Monoclonal Antibody Technology Propels Growth in Antivenom Market
    • Synthetic Antivenoms Expand Addressable Market Opportunity by Reducing Dependence on Animal Sources
    • Advancements in Biotechnology Strengthen Business Case for New Antivenom Developments
    • Increasing Focus on Neglected Tropical Diseases Accelerates Demand for Effective Antivenoms
    • Rising Awareness Among Rural Populations Generates Demand for Accessible Antivenom Treatments
    • Improved Distribution Networks in Remote Areas Throws the Spotlight on Market Expansion Potential
    • Personalized Medicine Trends Propel Growth in Tailored Antivenom Solutions
    • Shelf-Life Limitations of Antivenoms Generate Opportunities for Innovation in Storage Solutions
    • Emergence of Broad-Spectrum Antivenoms Impacts Market Growth Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antivenoms Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antivenoms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antivenoms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Antivenoms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Snakes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Snakes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Snakes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Scorpions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Scorpions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Scorpions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Spiders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Spiders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Spiders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Species by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Polyvalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Polyvalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Polyvalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Monovalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Monovalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Monovalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Anti-Venom Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Anti-Venom Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Anti-Venom Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • CHINA
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Antivenoms by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Antivenoms by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Antivenoms by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Antivenoms by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Antivenoms by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Antivenoms by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • INDIA
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Antivenoms by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Antivenoms by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Antivenoms by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Antivenoms by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Antivenoms by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Antivenoms by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030

IV. COMPETITION